Payment overview · 2025
General Payments
$329.26
17 reported records · 8 companies
Healthcare provider profile · identity verified
Carol S. Denney, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALBANY, KY · NPI 1730245655
Verified facts
What the public records show
CMS Open Payments records show Carol S. Denney, ARNP received $329.26 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.25 | 29.8% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.79 | 22.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.61 | 15.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.18 | 9.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.20 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.43 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.13 | 5.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.67 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.26 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $98.25 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $98.25 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $74.79 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.61 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 535 | 84 |
| Lisinopril | Lisinopril | 513 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 72 |
| Omeprazole | Omeprazole | 394 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 59 |
| Furosemide | Furosemide | 279 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 58 |
| Losartan Potassium | Losartan Potassium | 264 | 55 |
| Meloxicam | Meloxicam | 248 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 45 |
| Metformin Hcl | Metformin Hcl | 216 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 190 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 23 |
| Potassium Chloride | Potassium Chloride | 153 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 147 | 53 |
| Carvedilol | Carvedilol | 141 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 46 |
| Amoxicillin | Amoxicillin | 118 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 39 |
| Montelukast Sodium | Montelukast Sodium | 116 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 31 |
| Atenolol | Atenolol | 105 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 25 |
| Gabapentin | Gabapentin | 94 | 27 |
| Simvastatin | Simvastatin | 94 | 18 |
| Glimepiride | Glimepiride | 90 | 19 |
| Trazodone Hcl | Trazodone Hcl | 90 | 21 |
| Ezetimibe | Ezetimibe | 89 | 17 |
| Januvia | Sitagliptin Phosphate | 89 | 16 |
| Sertraline Hcl | Sertraline Hcl | 85 | 15 |
| Azithromycin | Azithromycin | 83 | 55 |
| Famotidine | Famotidine | 82 | 20 |
| Celecoxib | Celecoxib | 76 | 14 |
| Meclizine Hcl | Meclizine Hcl | 71 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 15 |
| Glipizide | Glipizide | 64 | 11 |
| Alendronate Sodium | Alendronate Sodium | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 16 |
| Clonidine Hcl | Clonidine Hcl | 62 | suppressed |
| Ibuprofen | Ibuprofen | 62 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 34 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Lorazepam | Lorazepam | 59 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Cefdinir | Cefdinir | 52 | 39 |
| Valsartan | Valsartan | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Cephalexin | Cephalexin | 50 | 37 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Eliquis | Apixaban | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 12 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Nystatin | Nystatin | 42 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Prednisone | Prednisone | 34 | 25 |
| Finasteride | Finasteride | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 24 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 24 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 13 |
| Risperidone | Risperidone | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 12 |
| Topiramate | Topiramate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.26 · 17 records | PFIZER INC. | CAPLYTA, FANAPT, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error